Since its commercial introduction a decade ago, the technique of dual-energ
y X-ray absorptiometry (DXA) has been widely recognized as a useful and sen
sitive method of measuring changes in bone mineral density (BMD) at selecte
d sites in the skeleton such as the spine and proximal femur. Because of th
eir high precision and stable calibration, DXA scanners are frequently used
in clinical trials to evaluate new treatments for osteoporosis. Quality as
surance procedures based on regular scanning of phantoms are widely adopted
in such trials, and continuity of the phantom BMD measurements is generall
y believed to ensure continuity in the in-vivo calibration. We report a cha
nge in calibration of a DXA scanner that occurred during a clinical trial w
here the calibration shift was different for the spine and femur sites and
was not predicted or explained by the standard quality control procedures u
sing phantoms. However, we show that provided patients enrolled in studies
are thoroughly randomized and the statistical analysis is confined to the d
ifferences between the treated and control groups, then the effects of such
calibration shifts on conclusions regarding the efficacy of treatment are
considerably smaller than the random statistical errors.